OncoMatch/Clinical Trials/Penile Cancer
Penile Cancer Clinical Trials
OncoMatch filters Penile Cancer trials by the molecular markers that determine eligibility — CD274, EGFR, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Penile Cancer trials
These are the molecular markers most commonly required or evaluated in Penile Cancer eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Penile Cancer trials
Ranked by phase and number of US sites. See all trials matched to your profile →
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Institute of Cancer Research, United Kingdom
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Christian Hinrichs
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Mayo Clinic
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Christian Hinrichs
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
How OncoMatch finds Penile Cancer trials for you
AI reads the protocol
Every Penile Cancer trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Penile Cancer and mark your biomarker results — CD274, EGFR — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.